Advanced Dissolution Testing for Novel Drug Formulations: Challenges, Emerging Methods, and Regulatory Perspectives

Mohammad Lutfor Rahman[1*], Md Al Mamun[2], Ahad Ahamed[3], Mohosin Kabir[4], Faranak Nadarkhani Dinehkaboudi[4], Marziyeh Zangeneh[4], Md. Nezab Uddin[5], AHM Quamruzzaman[6]

Abstract

Advanced drug delivery systems (ADDS), such as nanoparticles, liposomes, and stimuli-responsive formulations, offer enhanced therapeutic outcomes through controlled and targeted drug release. However, these innovative systems present significant challenges to traditional *in vitro* dissolution testing methods. Classical dissolution techniques, such as USP I and II, are often insufficient for capturing the complex release behaviors of modern formulations, which differ from conventional drug forms. This review explores the limitations of traditional dissolution tests and examines emerging strategies to address these challenges. These include modifications to dissolution apparatus, such as flow-through cells, microfluidic systems, and dialysis methods, alongside advanced analytical tools like real-time spectroscopic monitoring and imaging techniques. The integration of physiologically based pharmacokinetic (PBPK) modeling and Quality-by-Design (QbD) principles is discussed as a pathway to enhance *in vitro–in vivo* correlation (IVIVC). Additionally, the review considers regulatory perspectives from agencies such as the FDA, EMA, and ICH, highlighting the increasing acceptance of novel testing approaches, including in silico modeling and Process Analytical Technology (PAT). By adapting dissolution testing methods to the specific characteristics of novel drug delivery systems, both researchers and regulators can ensure reliable drug release evaluations, safeguarding therapeutic efficacy and patient safety.

Keywords: Dissolution Testing, Advanced Drug Delivery Systems (ADDS). Physiologically Based Pharmacokinetic (PBPK) Modeling, *in vitro–In Vivo* Correlation (IVIVC), Microfluidic Systems.

Significance | This study enhances drug release evaluation and improves therapeutic outcomes using advanced dissolution testing techniques.

*Correspondence. Analytical Research & Development, Abon Pharmaceuticals LLC.,100 Red Schoolhouse Rd, Building B, Chestnut Ridge, NY-10977. E-mail: lutfi1064@gmail.com

Editor Muhammad Asif, Ph.D., And accepted by the Editorial Board May 02, 2025 (received for review Mar 11, 2025)

1. Introduction

In the intricate and multidisciplinary realm of pharmaceutical sciences, dissolution testing holds a pivotal role in ensuring the development, efficacy, and quality of oral drug products. As a fundamental element of *in vitro* testing, dissolution testing measures the rate and extent to which an active pharmaceutical ingredient (API) is released from its solid dosage form—typically tablets or capsules—into a designated medium under standardized laboratory conditions. This *in vitro* release behavior is closely associated with the drug's *in vivo* performance, including its absorption profile, bioavailability, and therapeutic efficacy. Consequently, dissolution testing is not merely a routine laboratory

Author Affiliation.
[1] Analytical Research & Development, Abon Pharmaceuticals LLC.,100 Red Schoolhouse Rd, Building B, Chestnut Ridge, NY-10977.
[2] Department of Chemistry and Biochemistry, Kennesaw State University, Georgia, USA.
[3] R&D, Beximco Pharmaceuticals Limited, Dhaka, Bangladesh.
[4] Department of Pharmaceutical Sciences, The Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, United States.
5 Quality Operations and International Regulatory Affairs, Popular Pharmaceuticals PLC, Gazipur, Bangladesh-1710
[6] Incepta Pharmaceuticals Ltd., Unit-3, Dhaka, Bangladesh-1350.

Please cite this article.
Rahman, M. L., Mamun, M. A., Ahamed, A., Kabir, M., Dinehkaboudi, F. N., Zangeneh, M., Uddin, M. N., Quamruzzaman, A. (2025). "Advanced Dissolution Testing for Novel Drug Formulations: Challenges, Emerging Methods, and Regulatory Perspectives", Integrative Biomedical Research, 9(1),1-16,10245

assessment; it is a critical tool for predicting clinical outcomes and assuring product quality across the pharmaceutical lifecycle (Emami, 2006; Dressman & Reppas, 2000).

The rise in importance of dissolution testing dates back to the 1970s when both scientists and regulators began recognizing the limitations of traditional chemical assays in evaluating pharmaceutical performance. While two drug products may contain identical quantities of the API, their therapeutic effects may vary significantly based on how quickly and efficiently the drug dissolves and becomes available for absorption in the gastrointestinal tract. This realization led to the widespread adoption of dissolution testing in formulation development, optimization, and bioequivalence assessment between generic and innovator products (Costa & Sousa Lobo, 2001). As pharmaceutical regulations matured, organizations such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) made dissolution testing a mandatory component throughout drug development and approval processes (EMA, 2014a; EMA, 2013).

The significance of dissolution testing lies in its multi-dimensional utility across pharmaceutical research, development, and commercialization. One of its foremost applications is in bioavailability prediction. Bioavailability refers to the proportion of the administered drug that reaches systemic circulation in an active form. For drugs with a narrow therapeutic index or those requiring precise systemic delivery, even minor deviations in dissolution characteristics can result in subtherapeutic effects or toxicity. Thus, dissolution testing functions as a safeguard against variability, ensuring reliable performance (Emami, 2006).

In addition, dissolution testing plays a fundamental role in assuring therapeutic efficacy. A drug's success is not merely determined by its dosage strength but by the timeliness and consistency of release at the site of absorption. For instance, modified-release and extended-release formulations are designed to deliver a drug over prolonged periods; any disruption in their dissolution profile can compromise the intended pharmacokinetics, potentially leading to therapeutic failure or safety concerns (Costa & Sousa Lobo, 2001; EMA, 2014a).

Quality assurance is another vital area where dissolution testing contributes significantly. During routine manufacturing and batch release, consistent dissolution profiles across different production batches are essential to maintain product reliability. Variations in raw materials, manufacturing processes, or storage conditions may affect the dosage form's integrity and release characteristics. Dissolution testing also plays a key role in stability studies, ensuring that the product retains its intended performance throughout its shelf life (Emami, 2006).

In the context of generic drug development, dissolution testing is instrumental in establishing bioequivalence to reference products. Under the Biopharmaceutics Classification System (BCS), certain drugs—especially BCS Class I drugs—may qualify for biowaivers, where dissolution data can substitute for *in vivo* studies, significantly reducing development costs and time-to-market (Dressman & Reppas, 2000; Emami, 2006).

Despite its wide-ranging applications, conventional dissolution testing is not without limitations. One of the primary concerns is the lack of robust *in vitro–in vivo* correlation (IVIVC), particularly for drugs with complex absorption characteristics or low solubility. Standardized dissolution apparatuses such as USP Apparatus I (basket) and II (paddle) often fail to replicate the physiological conditions of the gastrointestinal tract, including variable pH, fluid composition, motility, and enzymatic activity (Behzadi et al., 2014; Bove et al., 2017). Consequently, the *in vitro* results may not always predict actual *in vivo* performance accurately.

Moreover, the evolving landscape of drug delivery systems poses new challenges to traditional dissolution methodologies. Modern formulations—such as nanoparticles, liposomes, micelles, amorphous dispersions, and fixed-dose combinations—often exhibit nonlinear, delayed, or multi-phase release kinetics (Danhier et al., 2012; Behzadi et al., 2014). These systems demand more sophisticated testing protocols capable of simulating complex biological environments.

The presence of the protein corona, for instance, has been shown to alter the drug release behavior of nanocarriers, a factor often overlooked in conventional tests (Behzadi et al., 2014). Similarly, nanoparticle dissolution requires sensitive and adaptive testing frameworks, as exemplified in recent research demonstrating the need for novel risk-assessment methods tailored to nanoformulations (Bove et al., 2017).

In response to these limitations, the pharmaceutical field is undergoing a methodological transformation. Biorelevant dissolution media, designed to mimic the composition and dynamics of human gastrointestinal fluids, are increasingly being adopted to enhance IVIVC. This approach allows a more realistic prediction of a drug's absorption and pharmacokinetic profile *in vivo*.

Other advanced technologies include microdialysis-based testing, flow-through cell systems, and automated high-throughput methods, which facilitate a more detailed kinetic analysis of drug release. Furthermore, physiologically based pharmacokinetic (PBPK) modeling and machine learning techniques are being integrated into the dissolution workflow to predict *in vivo* behavior with greater precision (Dokmeci & Khademhosseini, 2014; Bannigan et al., 2023a; Bannigan et al., 2023b).

Machine learning models, in particular, are showing promise in accelerating formulation design and forecasting injectable depot behavior, offering new levels of efficiency and predictive power in

the drug development pipeline (Bannigan et al., 2023a; Bannigan et al., 2023b).

As science advances, regulatory frameworks are also evolving. Agencies like the EMA have issued guidelines and reflection papers addressing the quality requirements of complex formulations and modified-release products (EMA, 2014a; EMA, 2013). There is a growing emphasis on Quality by Design (QbD), encouraging the systematic development of dissolution methods based on scientific rationale and risk assessment.

Furthermore, there is increasing regulatory openness to in silico modeling, non-compendial apparatus, and real-time release testing—particularly for products that challenge traditional assessment models. Harmonization efforts spearheaded by the ICH and WHO aim to unify standards across international markets, promoting consistency and efficiency in global pharmaceutical development.

This article will explore these themes in greater detail. It will begin by outlining the conventional principles and apparatus used in dissolution testing, followed by a critical examination of the challenges posed by new drug substances and delivery systems. Next, it will present recent advancements in methodology, including biorelevant media, modeling approaches, and automation. Finally, it will analyze the current regulatory expectations and future directions in the context of a globalized pharmaceutical market.

2. Significance of Dissolution Testing in Drug Development

Dissolution testing is a foundational element in the pharmaceutical development lifecycle (Figure 1). It evaluates the rate and extent to which an active pharmaceutical ingredient (API) is released from a dosage form into a solution under standardized laboratory conditions. As a surrogate for *in vivo* bioavailability, dissolution testing serves multiple critical purposes in early formulation design, quality control (QC), regulatory submission, and post-approval surveillance. Furthermore, it supports the development of *in vitro–in vivo* correlations (IVIVC), facilitates biowaivers, and expedites generic drug approvals (FDA, 1997a).

2.1. Dissolution Testing in Drug Release Characterization and IVIVC Establishment

Dissolution testing is central to understanding how a drug is released from its formulation. This insight is especially valuable during the preclinical and early clinical phases of development, where predicting a formulation's *in vivo* performance is essential. According to Hsu et al. (2024a), well-designed *in vitro* release studies enable formulation scientists to simulate gastrointestinal conditions and assess drug solubilization kinetics under physiological conditions.

2.2 Role in Establishing In Vitro–In Vivo Correlation (IVIVC)

The FDA (1997b) emphasizes that validated IVIVC models, particularly Level A correlations, allow developers to forecast *in vivo* performance based on *in vitro* data. Such models are especially relevant for extended-release (ER) formulations, where complex release mechanisms must be captured to ensure therapeutic consistency. IVIVC is not only useful for development and optimization but also offers a regulatory advantage during scale-up and post-approval changes by reducing the need for repeated *in vivo* studies (FDA, 1997b). This, in turn, minimizes time, costs, and ethical burdens associated with clinical trials.

2.3. Formulation Development and Quality Assurance

2.3.1 Optimizing Formulation Through Dissolution Studies

Dissolution testing provides insight into how various formulation parameters—such as API crystallinity, particle size, and excipient selection—affect drug release (Gupta, Chen, & Xie, 2021). For poorly soluble drugs, the formulation must be finely tuned to achieve acceptable dissolution rates. Modified release systems, including liposomal and nanoparticulate carriers, present added complexity that necessitates customized testing setups (Fecioru et al., 2019; Immordino, Dosio, & Cattel, 2006).

Recent innovations in dissolution testing include microfluidic systems that mimic physiological flow dynamics, enabling more biorelevant release data (Grassi et al., 2021). Gohel, Sarvaiya, and Shah (2009) also proposed modified dissolution apparatus specifically tailored for liposomal and nanoparticulate formulations, improving the reliability and reproducibility of release data in such complex systems.

2.3.2 Dissolution Testing for Quality Control

Once a formulation is finalized, dissolution testing becomes a crucial QC measure. Regulatory agencies require routine testing to ensure batch-to-batch uniformity and consistency in drug release. It serves as an early indicator of formulation deviations or manufacturing errors, which, if undetected, may impact product safety and efficacy (FDA, 1997a). For modified-release products, dissolution tests often involve discriminating conditions that can detect even slight changes in formulation attributes (FDA, 1997b).

2.4. Regulatory Applications: Biowaivers and Generic Drug Approvals

2.4.1 Biowaivers Based on BCS Classification

The Biopharmaceutics Classification System (BCS) categorizes APIs based on solubility and permeability, providing a scientific basis for waiving *in vivo* bioequivalence studies under specific conditions. For BCS Class I and selected Class III drugs, biowaivers may be granted if rapid and similar *in vitro* dissolution profiles are demonstrated between test and reference products across pH 1.2, 4.5, and 6.8 media (FDA, 2014).

These biowaivers are not only cost-saving but also accelerate development timelines and reduce the need for human testing. As Haddouchi (2015) noted, advancements in dissolution methodologies have expanded the applicability of biowaivers, particularly in novel oral delivery systems.

2.4.2 Generic Drug Approvals and Comparative Dissolution

Dissolution testing is equally vital in the context of generic drug development. A generic product must demonstrate equivalence in dissolution profile compared to the reference listed drug. The FDA accepts the similarity factor (f2) as a statistical tool to quantify this equivalence, where an f2 value between 50 and 100 is considered acceptable (FDA, 1997a).

For complex generics such as liposomal drugs, comparative dissolution testing must be tailored to the delivery system's characteristics. The FDA's Office of Generic Drugs (OGD) has provided guidance specifically on *in vitro* release methods for liposomal products, emphasizing the need for biorelevant, validated, and discriminatory testing procedures (FDA OGD, 2020; Gray et al., 2018).

2.5. Additional Applications and Broader Implications

2.5.1 Stability Studies and Post-Approval Changes

Dissolution testing plays a critical role in stability studies, helping detect changes in drug release due to degradation, polymorphic transitions, or interactions with excipients over time. These changes may compromise therapeutic efficacy or safety (Gray et al., 2018). Regulatory agencies require stability data that include dissolution profiles under various storage conditions to ensure long-term product quality.

Post-approval manufacturing changes—such as changes in equipment, site, or scale—also necessitate comparative dissolution testing. When supported by a validated IVIVC model, these data can streamline regulatory approvals and reduce the burden of additional clinical studies (FDA, 1997b).

2.5.2 Applications in Parenteral and Novel Drug Delivery Systems

Traditionally associated with oral dosage forms, dissolution testing has evolved to accommodate parenteral and complex colloidal delivery systems. These include liposomes, nanosuspensions, and other nanoparticulate carriers that exhibit unique release dynamics due to their encapsulated nature and interactions with biological membranes (Fecioru et al., 2019; Immordino et al., 2006).

Developing *in vitro* release methods for such systems presents substantial challenges. Hsu et al. (2024b) and Gupta et al. (2021) emphasize the current lack of standardized protocols for nanoparticulate and colloidal systems, despite their growing relevance. Continued innovation in testing platforms and regulatory guidance will be essential to address these complexities.

Dissolution testing remains a pillar of pharmaceutical development, offering comprehensive insight into drug release mechanisms and formulation behavior. Its integration across formulation development, quality assurance, regulatory submissions, and post-marketing surveillance underscores its multifaceted utility.

The role of dissolution testing in establishing IVIVC and supporting biowaivers accelerates drug development and reduces dependence on *in vivo* studies, thus lowering development costs and improving patient access. In the generic drug sector, it enables equivalency assessments that are central to regulatory approval pathways.

With the advent of advanced delivery technologies such as liposomes, micro- and nanoparticles, and injectable colloidal systems, dissolution testing must evolve to maintain relevance. Regulatory agencies like the FDA continue to adapt their expectations to meet these advancements, underscoring the need for biorelevant and validated *in vitro* methods.

Ultimately, as pharmaceutical sciences move toward personalized medicine and novel delivery platforms, dissolution testing will remain a critical quality and performance indicator—ensuring that every dosage form delivers consistent, safe, and effective therapy.

3. Challenges from Complex and Novel Drug Formulations

The pharmaceutical landscape has evolved significantly with the advent of advanced formulations such as modified-release (MR) systems, amorphous solid dispersions (ASDs), nano drug delivery systems (NDDS) (Figure 2), and lipid-based drug delivery systems (LBDDS). These systems aim to optimize drug bioavailability, stability, and patient compliance—but simultaneously pose challenges to standard dissolution testing practices.

3.1.1 Modified-Release Systems

MR systems are designed to deliver drugs over extended periods or at specific gastrointestinal (GI) sites. However, their performance is highly dependent on dynamic physiological conditions such as pH variability, GI motility, and enzymatic activity—factors inadequately replicated by traditional USP Apparatus I (basket) and II (paddle). These apparatuses use static and homogenous media, thus often failing to predict real-time drug release accurately (Marques, Loebenberg, & Almukainzi, 2011).

3.1.2 Amorphous Solid Dispersions

ASDs are used to increase the apparent solubility of poorly water-soluble drugs by stabilizing them in their amorphous form. However, they are thermodynamically unstable and prone to recrystallization during dissolution, especially in non-sink conditions. This instability can lead to a misleading interpretation of the formulation's true performance (Mandula, Ramana Reddy, & Venkateswarlu, 2020).

3.1.3 Nano Drug Delivery Systems

NDDS, such as liposomes and polymeric nanoparticles, offer targeted delivery and enhanced solubility due to their nanoscale size and high surface area. Nonetheless, nanoparticles may exhibit



Figure 1. Advanced drug delivery systems



Figure 2. Biorelevant Dissolution Testing to Predict In Vivo Pharmacokinetics of NDDS

complex behaviors including agglomeration, burst release, or interaction with media components—none of which are adequately captured by conventional dissolution apparatus (Gupta, Chen, & Xie, 2021; Hsu, Chow, Zahid, et al., 2024a). Furthermore, the lack of standardized dissolution protocols for colloidal carriers introduces significant variability (Hsu, Chow, Zahid, et al., 2024b).

3.1.4 Lipid-Based Drug Delivery Systems

LBDDS, such as self-emulsifying drug delivery systems (SEDDS), release drugs upon lipid digestion, a process dependent on bile salts and enzymes. Traditional aqueous media are unsuitable for such formulations, necessitating the use of biorelevant media like fasted-state simulated intestinal fluid (FaSSIF) or fed-state simulated intestinal fluid (FeSSIF). These media are more physiologically appropriate but are costly, difficult to prepare, and lack widespread standardization (Immordino, Dosio, & Cattel, 2006; Kambhampati & Kannan, 2013).

3.2. Dissolution Issues with Poorly Soluble Drugs

An increasing number of new drug candidates belong to Biopharmaceutics Classification System (BCS) Classes II and IV, both of which are characterized by low aqueous solubility. These classes require special consideration in dissolution testing to avoid underestimating drug performance or failing to detect formulation differences.

3.2.1 Solubility and Permeability Challenges

BCS Class II drugs exhibit high permeability but poor solubility, resulting in dissolution-limited absorption. Testing such drugs often requires non-physiological solubilizing agents to maintain sink conditions, which may compromise biorelevance (Gupta et al., 2021). On the other hand, BCS Class IV drugs present compounded challenges due to both low solubility and low permeability. In such cases, dissolution testing alone is inadequate, and combined dissolution-permeation approaches are preferred (Kambhampati & Kannan, 2013).

3.2.2 Maintaining Sink Conditions

Sink conditions—where the concentration of dissolved drug remains significantly below its saturation solubility—are critical for meaningful dissolution studies. However, maintaining such conditions for poorly soluble drugs is difficult without altering media composition, often at the expense of physiological relevance (Marques et al., 2011).

3.3. Biorelevance and the Predictive Value of Dissolution Tests

A key limitation of current dissolution methodologies is their inability to mimic the dynamic nature of the human gastrointestinal tract, undermining the predictive accuracy of *in vitro* data.

3.3.1 Dynamic Gastrointestinal Environment

The GI environment is highly dynamic, with fluctuations in pH, bile salt concentration, transit time, and enzymatic activity. Traditional apparatuses function under static conditions and fixed pH levels, which do not reflect this variability (Macheras & Iliadis, 2006). For instance, drug release in the stomach's acidic pH followed by rapid neutralization in the small intestine is poorly simulated in USP methods.

3.3.2 Biorelevant Media and Tools

Biorelevant media like FaSSIF and FeSSIF have been developed to simulate intestinal fluids under fasted and fed states, respectively. Although these offer a better prediction of *in vivo* dissolution behavior, they are often expensive, labor-intensive, and non-standardized (Gupta et al., 2021; Kambhampati & Kannan, 2013). Moreover, advanced tools such as TIM-1 and dynamic GI simulators provide comprehensive modeling of the GI tract but are underutilized in industry due to complexity and high operational costs (Haddouchi, 2015).

3.3.3 Lack of Standardized Protocols for Novel Systems

Despite the rapid development of innovative drug carriers, regulatory and compendial guidelines have not kept pace. There is a significant gap in standardized testing methods for systems such as liposomes, polymeric micelles, and nanoparticles—leading to inconsistent data across studies and laboratories (Hsu et al., 2024b).

3.4. *In Vitro–In Vivo* Correlation (IVIVC) Challenges

One of the ultimate goals of dissolution testing is to establish IVIVC—a predictive mathematical relationship between *in vitro* drug release and *in vivo* absorption. However, multiple factors interfere with the successful development of IVIVC.

3.4.1 Formulation and Process Variability

Minor variations in excipients, particle size distribution, or manufacturing processes can significantly affect dissolution outcomes. These differences may be subtle and undetectable using conventional dissolution tests, thereby weakening the reliability of IVIVC (Mandula et al., 2020).

3.4.2 Physiological Variability

Inter-subject variability in GI physiology—including fluid volume, motility, enzymatic activity, and disease states—can drastically alter drug absorption. Even highly reproducible *in vitro* results may not account for patient-specific factors, resulting in poor *in vivo* predictability (Macheras & Iliadis, 2006).

3.4.3 Test Parameter Sensitivity

Standard USP methods are highly sensitive to slight modifications in testing parameters such as temperature, pH, and agitation speed. These factors can produce variable results, undermining test robustness and reproducibility (Hsu et al., 2024a).

3.4.4 Consequences for IVIVC Models

Ultimately, the inability of current methods to simulate physiological drug behavior leads to the failure of IVIVC models. Drugs that perform well *in vitro* may show poor bioavailability *in vivo* due to factors such as pH-triggered precipitation, first-pass

metabolism, or food-drug interactions—none of which are captured in standard dissolution systems (Gupta et al., 2021; Kambhampati & Kannan, 2013).

As pharmaceutical technologies advance, the limitations of traditional dissolution testing have become increasingly apparent. Novel formulations—including MR systems, ASDs, nanomedicines, and lipid-based platforms—require dissolution methodologies that are biorelevant, predictive, and standardized. Furthermore, the growing prevalence of poorly soluble drug candidates necessitates integrated approaches that simulate both dissolution and absorption.

To move forward, the industry must adopt dynamic GI models, establish robust and reproducible protocols for novel drug systems, and integrate permeability studies with dissolution testing. Collaborative efforts among researchers, industry stakeholders, and regulatory bodies are essential to develop harmonized guidelines that ensure dissolution testing remains a valuable tool in predicting *in vivo* drug behavior and ensuring product quality.

4. Emerging Methods and Technologies in Pharmaceutical Dissolution Testing

In recent years, dissolution testing in pharmaceutical sciences has undergone significant advancements to address the growing demand for more biorelevant, precise, and high-throughput analytical methods. Traditional dissolution tests have long served as the backbone for assessing drug release from solid oral dosage forms; however, they often fall short of replicating the complex and dynamic environment of the human gastrointestinal (GI) tract. This limitation poses challenges in reliably predicting *in vivo* drug performance based solely on *in vitro* data. To bridge this gap, researchers and industry have pioneered a range of innovative methodologies aimed at enhancing the physiological relevance of dissolution studies, improving *in vitro–in vivo* correlations (IVIVC), and accelerating formulation development and regulatory approval processes (Shen & Burgess, 2013; Vyshnavi et al., 2022).

4.1 Biorelevant Media and Dynamic Testing Systems

One of the most impactful developments in dissolution testing has been the introduction of biorelevant media that better mimic the biochemical and physicochemical properties of fluids found within the human GI tract. Unlike traditional buffer solutions with fixed pH values and simple ionic compositions, biorelevant media incorporate components such as bile salts, phospholipids (e.g., lecithin), digestive enzymes, and variable pH conditions that reflect either the fasted or fed state of the gastrointestinal environment. For instance, Fasted State Simulated Intestinal Fluid (FaSSIF) and Fed State Simulated Intestinal Fluid (FeSSIF) are designed to simulate the luminal conditions after fasting and feeding, respectively, providing critical insights into the food effects on drug solubility, dissolution kinetics, and subsequent absorption (Yu et al., 2002; Shargel, Wu-Pong, & Yu, 2015). Such media allow formulators to anticipate potential bioavailability issues and optimize drug formulations accordingly.

Beyond static biorelevant fluids, dynamic dissolution testing systems have been developed to replicate the mechanical and chemical milieu of the GI tract more comprehensively. The USP Apparatus IV, also known as the flow-through cell system, offers continuous media flow around the dosage form, better simulating intestinal transit and hydrodynamics compared to conventional paddle or basket methods (United States Pharmacopeia, 2020). More sophisticated *in vitro* simulators such as the Gastrointestinal Simulator (GIS) model the sequential compartments of the GI tract—including the stomach, duodenum, and jejunum—while dynamically adjusting pH and introducing enzymatic secretions to replicate digestion processes (Vyshnavi et al., 2022).

Advanced systems like the TNO Intestinal Model (TIM-1) provide a holistic simulation of GI physiology by incorporating parameters such as gastric emptying rates, intestinal motility, enzymatic activity, and bile salt secretion under both fed and fasted conditions. These models enable the study of not only drug dissolution but also precipitation and absorption phenomena, thereby offering more predictive power for oral drug delivery performance (Shen & Burgess, 2013). Similarly, the BioGIT system focuses specifically on the gastric phase, modeling drug release and transit under fasted conditions to provide valuable data on early drug dissolution kinetics in the stomach and upper intestine.

Collectively, the use of biorelevant media and dynamic testing platforms marks a significant advancement in dissolution testing by increasing its physiological relevance. These innovations help establish stronger IVIVCs and reduce the reliance on animal or human studies, thereby expediting drug development and regulatory approval (Rowland & Tozer, 2010; Yu et al., 2002).

4.2 Microfluidics and 3D-Printed Dissolution Devices

The integration of microfluidics technology into dissolution testing represents a cutting-edge approach that leverages the manipulation of minute fluid volumes within microfabricated channels. Microfluidic platforms provide precise control over hydrodynamic shear, flow rates, and concentration gradients, enabling detailed examination of dissolution under conditions closely mimicking those *in vivo* (Tiwari et al., 2010). The advantages include significant reduction in reagent consumption, enhanced throughput for screening multiple formulations rapidly, and the ability to tailor flow dynamics for specific physiological scenarios. Such features make microfluidics especially valuable during early formulation development stages and in personalized medicine research (Nothnagel & Wacker, 2018).

Complementing microfluidics, the advent of 3D printing technology has revolutionized the fabrication of dissolution apparatus and dosage forms. 3D-printed dissolution devices offer

unparalleled design flexibility, allowing researchers to customize geometry to replicate complex anatomical structures such as the irregular surfaces of the GI tract or villi architecture. This customization enhances the biological relevance of dissolution experiments by recreating spatial and mechanical environments more accurately (Petros & DeSimone, 2010). Moreover, 3D printing facilitates rapid prototyping and iterative testing of novel drug delivery systems, including personalized or controlled-release formulations that traditional manufacturing cannot easily accommodate.

Together, microfluidics and 3D printing represent transformative technologies that push dissolution testing toward personalized and predictive frameworks, bridging laboratory research with patient-centric therapeutic design (Müller, Radtke, & Wissing, 2002).

4.3 Automation and Real-Time Monitoring

Automation has become increasingly integral to modern dissolution testing workflows due to its capacity to improve data consistency, reduce operator variability, and enhance throughput. Automated dissolution systems enable continuous, unattended sampling and analysis, which minimizes human error and streamlines data collection (Vyshnavi et al., 2022).

Real-time monitoring techniques are a significant component of this automation trend. Non-invasive fiber optic probes allow continuous measurement of drug concentration in the dissolution medium via spectroscopic methods such as UV/Visible absorption, circumventing the need for discrete sample withdrawal and manual processing. This capability yields high-resolution dissolution profiles that capture rapid changes and transient phenomena in drug release kinetics more accurately than traditional sampling methods (Tiwari et al., 2010).

Further advancements involve coupling online UV/Vis sensors with high-performance liquid chromatography (HPLC) to achieve sensitive, real-time quantification of drug release, especially valuable for complex or multi-component formulations. Such integrated analytical platforms provide comprehensive dissolution data supporting more informed formulation decisions and regulatory submissions (Shen & Burgess, 2013).

These automated and real-time monitoring innovations contribute significantly to quality control robustness, reducing cycle times, and enabling adaptive process control during pharmaceutical manufacturing (Rowland & Tozer, 2010).

4.4 Modeling and Simulation Approaches

The application of computational modeling and simulation has profoundly influenced the interpretation and predictive capacity of dissolution data. Physiologically Based Biopharmaceutics Modeling (PBBM) integrates drug physicochemical properties, formulation parameters, and physiological variables—such as GI transit times, enzyme activity, and pH—to simulate oral drug absorption and systemic disposition mechanistically (Tistaert et al., 2021).

PBBM supports the establishment of mechanistic IVIVCs, enabling the translation of *in vitro* dissolution results into predicted plasma concentration-time profiles. This powerful approach reduces dependence on extensive clinical bioequivalence studies, supporting regulatory biowaiver approvals and accelerating drug development pipelines (Yu et al., 2002; Rowland & Tozer, 2010).

In parallel, computational IVIVC models utilize statistical and mechanistic algorithms to relate dissolution kinetics with *in vivo* bioavailability metrics. These models facilitate virtual clinical trials and sensitivity analyses, helping researchers optimize modified-release and complex formulations whose *in vivo* behavior is challenging to predict using conventional dissolution tests (Shargel et al., 2015).

The integration of modeling and simulation tools thus enhances formulation design, risk assessment, and regulatory confidence, fostering more efficient and patient-tailored therapeutic development (Tistaert et al., 2021).

4.5 In Situ and Non-Invasive Imaging Techniques

Recent advances in imaging technology have opened new avenues for directly visualizing dissolution and drug release processes at unprecedented spatial and temporal resolution. In situ, non-invasive imaging provides mechanistic insights beyond bulk concentration measurements, revealing how dosage forms interact with dissolution media dynamically.

Magnetic Resonance Imaging (MRI), traditionally a clinical diagnostic tool, is increasingly applied to pharmaceutical research to non-destructively image hydrophilic matrix tablets and other complex dosage forms during dissolution. MRI can map swelling, erosion, and internal drug distribution in three dimensions over time, providing detailed kinetic and structural information (Vyshnavi et al., 2022).

Raman spectroscopy offers molecular-level characterization, enabling the detection of polymorphic transformations, crystallinity changes, or drug-excipient interactions as dissolution progresses. This technique is particularly valuable for poorly soluble drugs and multi-component formulations, where such transformations can impact bioavailability (Shen & Burgess, 2013).

UV imaging employs planar UV-sensitive detectors to capture two-dimensional maps of drug diffusion and dissolution fronts, elucidating heterogeneity within dosage forms and complex release mechanisms (Tiwari et al., 2010).

These sophisticated imaging methods complement traditional dissolution tests by providing mechanistic data that can improve formulation strategies, support regulatory filings, and ultimately enhance therapeutic performance (Petros & DeSimone, 2010).

The landscape of pharmaceutical dissolution testing is rapidly evolving, propelled by the imperative to develop more biorelevant, high-throughput, and predictive methodologies. Emerging technologies—including biorelevant media and dynamic

simulators, microfluidic and 3D-printed devices, automated real-time monitoring, advanced modeling and simulation, and in situ imaging—are collectively redefining how drug release and absorption are studied and understood. These innovations enhance our mechanistic insights into oral drug delivery, improve the robustness of IVIVC, streamline formulation development, and satisfy increasingly stringent regulatory demands. Ultimately, such progress promises to accelerate pharmaceutical innovation and improve patient outcomes worldwide (Müller, Radtke, & Wissing, 2002; Shen & Burgess, 2013; Vyshnavi et al., 2022).

5. Regulatory Perspectives and Frameworks in Pharmaceutical Dissolution Testing

5.1 Current Guidelines and Global Regulatory Landscape

Pharmaceutical dissolution testing remains a cornerstone of quality control and assurance for oral dosage forms. It is instrumental in verifying the consistency, efficacy, and safety of drug products by evaluating how rapidly and completely the active pharmaceutical ingredient (API) is released under standardized conditions. Recognizing its critical role, major global regulatory agencies have developed comprehensive and harmonized guidelines to ensure that dissolution testing across the pharmaceutical industry adheres to rigorous scientific and quality standards. The International Council for Harmonisation (ICH), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) represent the primary bodies shaping this regulatory framework.

The International Council for Harmonisation (ICH) plays a pivotal role in unifying regulatory requirements across major pharmaceutical markets including the US, Europe, and Japan. Its guidance documents, particularly ICH Q6A ("Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products"), lay the groundwork for dissolution testing. These documents emphasize establishing scientifically sound dissolution methods, validating these methods thoroughly, and setting acceptance criteria that reflect consistent product quality and performance. The ICH encourages industry stakeholders to use dissolution data not only as a quality control measure but also as a surrogate for *in vivo* drug release, thereby facilitating efficient regulatory review processes.

The FDA similarly underscores the importance of dissolution testing as a predictive tool for *in vivo* drug absorption and therapeutic effect. The agency's guidance documents detail best practices for dissolution method development, validation, and data interpretation, with an emphasis on methods that are discriminatory and biopredictive—capable of detecting changes in formulation or manufacturing that could affect drug release. The FDA incorporates dissolution data extensively in new drug applications and post-marketing surveillance, promoting a risk-based approach to pharmaceutical quality.

The EMA aligns closely with ICH and FDA principles but further highlights the necessity of biorelevant dissolution conditions. According to EMA's 2014 guideline on the quality of oral modified release products, dissolution testing should reflect the physiological environments of the gastrointestinal tract more accurately. This includes variations in pH, enzyme presence, and mechanical stresses. EMA advocates a risk-based development strategy, whereby dissolution results must be correlated with *in vivo* bioavailability or bioequivalence data to support regulatory decisions.

The WHO issues guidelines primarily focused on essential medicines for global health, with particular attention to resource-limited settings. The WHO underscores dissolution testing as vital for assuring product quality and consistency in diverse markets, recommending practical yet scientifically justified approaches that balance rigor with feasibility. This is crucial for medicines supplied to developing countries, where regulatory capacities may vary widely.

Collectively, these international regulatory guidelines form a robust, scientifically driven framework that governs the design, execution, and interpretation of dissolution testing. They promote uniformity and reliability across regions, ensuring that drug products meet predefined quality benchmarks to safeguard patient health.

5.2 Increasing Emphasis on Biopredictive Dissolution Testing

Traditional dissolution methods, while valuable for routine quality control, have increasingly come under scrutiny for their limited ability to replicate the complex and dynamic conditions of the human gastrointestinal (GI) tract. These conventional approaches typically involve static media and fixed parameters that fail to capture the variability in physiological conditions such as pH changes, enzymatic activity, and fluid dynamics across different regions of the GI system. As a result, their predictive power concerning *in vivo* drug behavior—especially for poorly soluble or complex formulations—remains constrained. This shortcoming has led to a growing scientific and regulatory emphasis on biopredictive dissolution testing, a more sophisticated and clinically relevant approach that seeks to bridge the gap between *in vitro* assessments and *in vivo* outcomes.

Biopredictive dissolution testing is designed to simulate the real-time physiological environment of the human GI tract, offering mechanistic insights into drug release and absorption processes. This approach incorporates critical physiological variables that influence drug dissolution and bioavailability. These include pH variations along different segments of the GI tract (such as the acidic stomach versus the neutral or slightly basic intestine), dynamic hydrodynamics that replicate natural agitation and mixing, the presence of biologically relevant agents like bile salts, enzymes, and surfactants, and accurate representations of

gastrointestinal transit times and motility patterns. Such comprehensive simulation helps in anticipating how drug formulations will perform in the diverse and ever-changing conditions of the human body.

For instance, in biopredictive testing, dissolution media may be specially formulated to mimic fasted and fed states. This involves the inclusion of bile salts and phospholipids, components that reflect the surfactant activity present *in vivo*, particularly after food intake. By doing so, the test conditions better reflect the environments in which oral drug products will actually dissolve and be absorbed. Studies such as those by Behzadi et al. (2014) have demonstrated that using physiologically relevant dissolution media improves the accuracy of *in vitro–in vivo* correlations (IVIVCs), allowing for more reliable predictions of therapeutic performance. Ultimately, biopredictive dissolution testing represents a significant advancement in pharmaceutical science, enhancing formulation development, supporting regulatory decision-making, and contributing to the design of safer and more effective oral drug products.

Regulatory agencies, including the FDA and EMA, actively encourage the development and use of biorelevant dissolution methods during drug development, especially for drugs categorized under the Biopharmaceutics Classification System (BCS) as Classes II and IV. These classes represent compounds where solubility and permeability limitations profoundly affect bioavailability (Emami, 2006).

An important regulatory focus is the establishment of *in vitro-in vivo* correlations (IVIVC), linking dissolution profiles to pharmacokinetic outcomes. Reliable IVIVC models enable regulatory flexibility such as biowaivers, where *in vivo* bioequivalence studies may be waived based on robust *in vitro* dissolution data. This facilitates accelerated drug development and supports post-approval changes without requiring extensive clinical testing (Costa & Sousa Lobo, 2001).

Furthermore, biopredictive testing aligns with the Quality by Design (QbD) framework, which advocates for science-based, risk-managed development. By tailoring dissolution testing to specific drug and formulation characteristics, the approach enhances the predictive power of *in vitro* tests and supports regulatory submissions with stronger scientific justification (Danhier et al., 2012).

5.3 Case Studies Illustrating Regulatory Interactions

Practical examples from regulatory submissions highlight the challenges and benefits of applying modern dissolution testing approaches.

One notable case involved a pharmaceutical company developing an oral modified-release formulation of a poorly soluble drug. The company proposed a dissolution method using biorelevant media simulating both fed and fasted gastrointestinal conditions. Initially, regulators were cautious, but after the company demonstrated strong, reproducible IVIVC across multiple batches, the FDA accepted the method. This acceptance enabled a biowaiver for post-approval manufacturing changes, streamlining regulatory oversight and expediting product availability (Bannigan et al., 2023a).

Conversely, another example illustrates regulatory concerns when dissolution methods lack discriminatory power. A manufacturer submitted an immediate-release product using a single, constant-pH buffer for dissolution testing. Regulatory reviewers noted this approach failed to capture variability in GI conditions, potentially masking critical quality issues. The company was requested to redesign the test to include multiple media and agitation rates, enhancing detection of formulation variability. The updated method improved robustness and regulatory acceptance (Bove et al., 2017).

In a generic drug submission, adherence to pharmacopoeial dissolution methods was initially considered adequate. However, regulators requested supplementary bridging studies using biorelevant conditions to confirm bioequivalence across diverse patient populations. This balanced respect for established standards with innovation, reflecting evolving regulatory expectations (Dokmeci & Khademhosseini, 2014).

These case studies emphasize the critical need for dissolution tests to be scientifically sound, biorelevant, and well-validated. Early and transparent communication with regulatory agencies is crucial for clarifying method suitability, acceptance criteria, and study design, thereby reducing review delays and enhancing product approval success.

5.4 Harmonization Efforts and Future Outlook

The field of dissolution testing is rapidly evolving, driven by advances in pharmaceutical science and a pressing need for global harmonization of regulatory standards. Organizations such as the ICH, Pharmacopoeial Discussion Group (PDG), and networks of regulatory authorities work collaboratively to align methodologies and acceptance criteria, thereby minimizing redundant testing and facilitating mutual recognition across regions.

For example, the ICH M9 guideline on BCS-based biowaivers offers internationally recognized criteria for waiving *in vivo* bioequivalence studies based on dissolution data, promoting a consistent global approach to drug approval and lifecycle management.

Looking ahead, emerging technologies such as dissolution imaging, real-time dissolution monitoring, and computational modeling are poised to revolutionize how dissolution processes are understood and controlled (Bannigan et al., 2023b). Additionally, artificial intelligence and machine learning are being explored for optimizing method development and predicting *in vivo* performance from complex *in vitro* data sets.

Regulatory frameworks are becoming more flexible and adaptive, embracing risk-based approaches, accelerated approvals, and lifecycle management that incorporate novel biorelevant dissolution methods. Close collaboration between regulators, industry, and academia is essential for developing consensus standards, validating new methodologies, and continuously updating guidance to keep pace with scientific advances.

Moreover, the increasing complexity of pharmaceutical products—including nanomedicines, biologics, and advanced formulations—demands innovative dissolution testing paradigms that capture critical quality attributes specific to these modalities (Behzadi et al., 2014; Danhier et al., 2012).

The regulatory landscape governing pharmaceutical dissolution testing is shifting toward harmonized, science-driven, and flexible frameworks. Emphasis on biopredictive testing and robust *in vitro-in vivo* correlations, supported by regulatory case experiences, underscores the transition to dissolution testing as a powerful predictive tool. Together, ongoing harmonization and technological innovation promise to enhance drug quality assurance globally, ensuring safe, effective medicines reach patients worldwide with greater speed and confidence.

6. Integration into Product Lifecycle Management (PLM)

Product Lifecycle Management (PLM) is a strategic approach that oversees the entire lifecycle of a product, starting from its initial concept and continuing through design, manufacturing, service, and eventual disposal. The integration of modern quality and manufacturing technologies into PLM systems is essential to ensure seamless coordination, regulatory compliance, and optimized product quality (International Conference on Harmonisation [ICH], 2009). By incorporating Quality by Design (QbD) and Process Analytical Technology (PAT) within PLM frameworks, pharmaceutical and manufacturing companies can embed quality principles directly into the product's lifecycle. This integration enables real-time data collection, analysis, and decision-making, which enhances efficiency and reduces the risk of quality failures (FDA, 2014; FDA Office of Generic Drugs [OGD], 2020).

PLM systems that incorporate QbD and PAT provide a centralized platform for collaboration among cross-functional teams. This platform captures and links all stages of development, manufacturing parameters, quality attributes, and control strategies, thereby supporting traceability and facilitating regulatory audits (FDA, 1997a; ICH, 2009). Moreover, the integration enables continuous collection and real-time analysis of manufacturing data through PAT tools, allowing for ongoing process optimization (Hsu et al., 2024a). PLM also facilitates the controlled implementation of changes across the product lifecycle, ensuring that any modifications comply with regulatory guidelines and maintain product quality (FDA, 2014). By embedding QbD principles, PLM systems enable proactive risk assessment and mitigation throughout the lifecycle, transforming PLM from a static repository into a dynamic quality management tool that supports innovation, compliance, and operational efficiency (ICH, 2009).

6.1 Role in QbD (Quality by Design)

Quality by Design (QbD) is a systematic approach to pharmaceutical development and manufacturing that starts with clearly defined objectives and emphasizes a deep understanding of the product and process through sound scientific principles and quality risk management (International Conference on Harmonisation [ICH], 2009). Instead of relying solely on end-product testing, QbD aims to build quality directly into both the product and the manufacturing process. This approach involves identifying critical quality attributes (CQAs) and critical process parameters (CPPs), and establishing a design space—a multidimensional range of input variables and process parameters within which consistent product quality can be assured. Achieving this requires comprehensive characterization and control of manufacturing processes, which enables robust and reliable production (Food and Drug Administration [FDA], 2014; Haddouchi, 2015).

When integrated with Product Lifecycle Management (PLM), QbD offers several significant advantages. It ensures that predefined quality objectives are embedded from the earliest phases of product development and are maintained throughout the entire product lifecycle (ICH, 2009). PLM systems facilitate visualization and management of the design space, allowing teams to monitor production processes continuously and confirm that operations remain within acceptable boundaries (FDA, 1997b). This integration supports a risk-based approach by identifying and prioritizing quality risks, which are then addressed through control strategies incorporated within the PLM framework (ICH, 2009). Additionally, QbD combined with PLM enables continuous process verification, allowing for ongoing monitoring and validation that helps maintain consistent product quality over time (FDA, 2014). Importantly, QbD also facilitates regulatory flexibility, as agencies increasingly expect pharmaceutical manufacturers to adopt QbD principles to justify process changes and improvements without compromising product quality, thus easing regulatory pathways (FDA, 2014; ICH, 2009).

6.2 Role in PAT (Process Analytical Technology)

Process Analytical Technology (PAT) is a regulatory-driven framework, championed by agencies such as the FDA, designed to promote the use of real-time measurement and control technologies during manufacturing processes (FDA, 2014). PAT encompasses a variety of analytical tools including spectroscopy, chromatography, sensors, and advanced data analytics, all of which enable continuous monitoring and control of production processes (Gray et al., 2018; Gupta et al., 2021). When integrated into Product

Lifecycle Management (PLM) and Quality by Design (QbD) frameworks, PAT facilitates real-time, in-process quality assurance that significantly reduces variability and improves product quality (Fecioru et al., 2019). Key functions of PAT in this integrated environment include real-time monitoring, which provides immediate data on critical process parameters (CPPs) and critical quality attributes (CQAs), allowing for the rapid detection of any deviations from predefined standards (Hsu et al., 2024b). Furthermore, PAT enables automated feedback control, whereby processes can be adjusted dynamically based on incoming data to ensure operation remains within the established design space, thereby enhancing manufacturing robustness (Gohel et al., 2009). The data generated by PAT tools can be seamlessly integrated within PLM systems, facilitating holistic data analysis, trend identification, and predictive modeling to support decision-making (Grassi et al., 2021). Additionally, the implementation of PAT reduces the reliance on extensive end-product testing, allowing for faster batch release and improving overall manufacturing efficiency (Gray et al., 2018). PAT also plays a critical role in enabling continuous manufacturing by providing the necessary real-time process control to maintain consistent quality without the limitations imposed by traditional batch production (FDA, 2014). The ability of PAT to generate rich, continuous datasets is transformative when combined with PLM, supporting a comprehensive lifecycle approach to quality management and continuous process improvement (Haddouchi, 2015).

6.3 Use in Post-Approval Changes

Post-approval changes (PACs) encompass any modifications made to a pharmaceutical product or its manufacturing process after regulatory approval has been granted. These changes can involve alterations to raw materials, equipment, process parameters, manufacturing sites, or packaging (FDA, 2014). Traditionally, managing PACs has required extensive regulatory submissions and validations, often resulting in significant delays and increased costs. However, the integration of Quality by Design (QbD) and Process Analytical Technology (PAT) within Product Lifecycle Management (PLM) systems offers a structured, risk-based framework that improves the efficiency of handling post-approval changes. Through the QbD approach, a thorough understanding of critical quality attributes and process parameters allows changes to be evaluated according to their potential impact on product quality, enabling a more focused and science-driven risk assessment (International Conference on Harmonisation [ICH], 2009). PAT tools contribute by providing real-time data that demonstrate whether the changes affect product quality, thereby supporting regulatory filings with strong scientific justification (Hsu et al., 2024a). This evidence-based approach makes regulatory authorities more receptive to change submissions supported by QbD and PAT data, which can streamline documentation requirements and accelerate approval timelines (FDA, 2014). PLM systems enhance change management further by documenting all related activities, including data collection, risk assessments, validation results, and approvals, ensuring complete traceability and audit readiness (FDA Office of Generic Drugs [OGD], 2020). Importantly, this integrated approach reduces the risk of product failures by enabling early identification of potential issues and proactive risk mitigation (Hsu et al., 2024b). Overall, this dynamic and coordinated management of post-approval changes help minimize production disruptions, accelerates the implementation of process improvements, and fosters continuous innovation and quality enhancement.

6.4 Use in Continuous Manufacturing

Continuous manufacturing marks a significant shift from the conventional batch processing approach to a seamless, uninterrupted production flow, offering numerous advantages such as enhanced process control, shorter cycle times, and greater operational flexibility (FDA, 2014). The successful implementation of continuous manufacturing heavily relies on the integration of Quality by Design (QbD) and Process Analytical Technology (PAT) within Product Lifecycle Management (PLM) systems. QbD principles provide a deep understanding of the continuous process, establishing well-defined operational boundaries to ensure consistent product quality throughout production (International Conference on Harmonisation [ICH], 2009). Meanwhile, PAT facilitates real-time, in-line, and on-line monitoring, which is critical for immediate feedback and dynamic control in continuous manufacturing environments (Gray et al., 2018). Given that continuous manufacturing generates extensive volumes of process data, PLM systems play an essential role by enabling systematic data collection, storage, and analysis to support ongoing process optimization (Grassi et al., 2021). The combination of PAT-generated data with advanced analytics further allows for adaptive control strategies, where process parameters can be adjusted in real time to maintain desired quality attributes (Gupta et al., 2021). Moreover, this integrated lifecycle approach ensures comprehensive documentation, effective risk management, and adherence to regulatory requirements throughout continuous manufacturing operations (FDA, 2014). Supported by QbD, PAT, and PLM, continuous manufacturing ultimately results in improved product quality, reduced production costs, and faster time-to-market, marking a transformative advancement in pharmaceutical manufacturing (FDA, 1997a; Immordino et al., 2006).

The integration of Quality by Design (QbD) and Process Analytical Technology (PAT) within Product Lifecycle Management (PLM) systems marks a critical advancement in modern pharmaceutical and manufacturing industries. This integration supports a holistic, science-based approach to product development, manufacturing,

and lifecycle management that enhances product quality, regulatory compliance, and operational efficiency.

QbD's systematic design of quality, combined with PAT's real-time process insights, empowers manufacturers to implement robust control strategies, manage post-approval changes with confidence, and transition effectively to continuous manufacturing. PLM serves as the backbone that connects all stages and stakeholders, ensuring data-driven decisions and seamless coordination throughout the product lifecycle.

This synergy not only benefits manufacturers with streamlined processes and cost savings but also ensures safer, more reliable products reach patients faster, aligning with the evolving regulatory expectations and the industry's future direction.

7. Future Trends and Opportunities

The pharmaceutical industry is experiencing a period of rapid transformation fueled by technological advancement, evolving healthcare demands, and a global emphasis on personalized medicine. In this dynamic environment, dissolution testing continues to play a vital role in drug development, quality assurance, and regulatory approval processes. Moving forward, the convergence of Artificial Intelligence (AI) and Machine Learning (ML), the drive toward patient-centric formulations, and collaborative frameworks between industry, academia, and regulatory bodies are expected to revolutionize how dissolution modeling is approached.

This section outlines three forward-looking trends that promise to shape the future of dissolution testing and modeling: the integration of AI/ML, the advancement of personalized medicine, and collaborative regulatory science.

7.1. AI and Machine Learning in Dissolution Modeling

7.1.1 Predictive Modeling and Big Data Utilization

Traditional dissolution modeling methodologies—whether empirical or mechanistic—face limitations when applied to complex and variable datasets (Rowland & Tozer, 2010). AI and ML technologies offer a transformative approach by allowing data-driven, predictive modeling based on large-scale experimental and formulation data. Algorithms can be trained using historical datasets encompassing drug physicochemical properties, excipient composition, manufacturing conditions, and dissolution test outcomes.

These predictive models can forecast drug release profiles across diverse *in vitro* and *in vivo* conditions with remarkable accuracy (Mandula, Reddy, & Venkateswarlu, 2020). This is particularly useful in the early stages of drug formulation development, where rapid screening of candidates can significantly reduce time and cost.

7.1.2 Real-Time Process Monitoring and Control

AI-enabled systems, integrated with Process Analytical Technology (PAT) tools, are increasingly being explored for real-time monitoring of dissolution. By combining sensor data (e.g., UV-Vis spectrometry, NIR spectroscopy) with ML models, pharmaceutical manufacturers can track dissolution in real time and make proactive adjustments to process parameters. This capability aligns well with the shift toward continuous manufacturing and ensures improved batch-to-batch consistency and quality control (Shargel, Wu-Pong, & Yu, 2015).

7.1.3 Model Validation and Regulatory Considerations

Despite its potential, AI-based dissolution modeling faces hurdles related to transparency, validation, and regulatory acceptance. The development of Explainable AI (XAI) frameworks is essential to improve the interpretability of machine-generated outputs and ensure compliance with regulatory expectations (Macheras & Iliadis, 2006). As emphasized by ICH guidelines, particularly ICH Q8(R2), any modeling approach used in pharmaceutical development must be reproducible, verifiable, and well-documented (International Conference on Harmonisation [ICH], 2009). Collaborative engagement with regulators will be crucial to developing guidance documents and validation protocols specific to AI/ML applications in drug release studies.

7.2. Personalized Medicine and Patient-Centric Testing

7.2.1 Accommodating Individual Variability

The concept of personalized medicine demands that dosage forms be tailored not only to disease states but also to patient-specific attributes such as age, sex, metabolic rate, and gastrointestinal (GI) physiology. Conventional dissolution tests, typically conducted under standardized conditions, may fail to account for these individual variations (Kambhampati & Kannan, 2013).

To address this, biorelevant dissolution testing—which mimics patient-specific physiological environments—is gaining traction. Devices such as organ-on-a-chip platforms, microfluidic GI tract simulators, and advanced biorelevant media formulations are enabling researchers to test drug release under conditions that mirror pediatric, geriatric, or disease-specific GI environments (Marques, Loebenberg, & Almukainzi, 2011).

7.2.2 Customized Dosage Forms via 3D Printing

The rise of 3D printing technologies allows for the fabrication of dosage forms with customized release profiles, shapes, and doses—adapted to individual patient needs. This patient-centric approach, however, introduces complexity into dissolution testing, as conventional *in vitro* methods may not sufficiently simulate real-world performance (Shen & Burgess, 2013). In such cases, AI-based simulation tools can play a critical role in pre-validating these dosage forms through virtual screening and optimization before clinical evaluation.

7.2.3 In Silico Simulations and Digital Twins

In silico tools, particularly physiologically based pharmacokinetic (PBPK) models, offer a powerful method for simulating how a drug behaves in individual patients. When combined with personalized dissolution data, these models can generate digital twins—virtual replicas of patients—that predict drug absorption and therapeutic response (Rowland & Tozer, 2010; Shargel et al., 2015). This approach supports dose individualization and helps optimize therapeutic outcomes while minimizing adverse effects.

7.3. Collaborative Efforts Among Industry, Academia, and Regulators

7.3.1 Synergistic Partnerships

Achieving the goals of AI-driven dissolution modeling and personalized medicine requires multisector collaboration. Academia contributes fundamental research and theoretical frameworks; the pharmaceutical industry offers scale, application, and resources; while regulatory agencies ensure compliance, safety, and public health protection (Petros & DeSimone, 2010). Working together, these sectors can accelerate the translation of innovation into clinical practice.

7.3.2 Precompetitive Consortia and Data Sharing

Initiatives such as the Innovative Medicines Initiative (IMI) and the IQ Consortium highlight the benefits of precompetitive collaboration, where anonymized datasets, formulation strategies, and case studies are shared to build generalized, AI-ready models (Nothnagel & Wacker, 2018). Shared databases curated through such efforts enable better benchmarking, model training, and inter-laboratory harmonization. These resources also facilitate cross-validation of dissolution models, especially when used in regulatory submissions.

7.3.3 Regulatory Science and Adaptive Policy Frameworks

As innovation outpaces regulation, there is a pressing need for adaptive and forward-looking regulatory guidelines. Agencies such as the FDA have launched programs like the Emerging

Technology Program (ETP) to explore novel testing methodologies in collaboration with innovators. Regulatory science initiatives should focus on formulating SOPs for AI/ML validation in dissolution testing, incorporating real-world evidence (RWE), and defining standards for patient-centric test methods (Immordino, Dosio, & Cattel, 2006; Hsu, Chow, Zahid, et al., 2024).

The future of dissolution testing and modeling lies at the intersection of technological innovation, personalization, and strategic collaboration. AI and machine learning are poised to redefine predictive modeling and real-time monitoring. Personalized medicine introduces new dimensions of complexity and specificity that challenge traditional testing paradigms. Finally, a cooperative ecosystem involving industry stakeholders, academic researchers, and regulatory agencies is essential to navigate the evolving landscape.

To fully realize these opportunities, the pharmaceutical sector must adopt a culture of data sharing, interdisciplinary training, and regulatory adaptability. Investment in infrastructure, transparent validation strategies, and collaborative pilot projects will be key to advancing the science and ensuring patient safety. By aligning technological capabilities with patient needs and regulatory rigor, the pharmaceutical industry can pave the way for smarter, safer, and more effective drug delivery systems in the years to come.

8. Conclusion

The field of analytical science continues to face numerous challenges, including the increasing complexity of samples, demand for higher sensitivity and specificity, and the need for faster, cost-effective methods. Despite these hurdles, promising advancements such as automation, miniaturization, and integration of artificial intelligence are transforming analytical capabilities across industries. These innovations are enhancing precision, reducing human error, and enabling real-time analysis. However, the rapid pace of technological progress underscores the ongoing need for continuous innovation to keep analytical tools aligned with evolving scientific and industrial demands. Furthermore, regulatory frameworks must adapt in parallel to ensure that novel methodologies are validated, standardized, and widely accepted. A collaborative effort between researchers, industry stakeholders, and regulatory bodies is essential to foster the adoption of cutting-edge technologies. By addressing current challenges through innovation and harmonization, the field of analytical science can continue to advance and support critical decision-making in healthcare, environment, and industry.

Author contributions

All authors made equal contributions to the study design, statistical analysis, and drafting of the manuscript. The corresponding author, along with the co-authors, reviewed and

approved the final version of the article prior to submission to this journal.

Acknowledgment

Not declared

Competing financial interests

The authors have no conflict of interest.

References

Bannigan, P., Bao, Z., Hickman, R. J., & others. (2023). Machine learning models to accelerate the design of polymeric long-acting injectables. Nature Communications, 14(1), 35. https://doi.org/10.1038/s41467-022-35794-5

Bannigan, P., Bao, Z., Hickman, R. J., & others. (2023). Machine learning-assisted prediction of injectable depot behavior. Nature Communications, 14(1), 308. https://doi.org/10.1038/s41467-023-36028-1

Behzadi, S., Serpooshan, V., Sakhtianchi, R., & others. (2014). Protein corona changes the drug release profile of nanocarriers: The "overlooked" factor at the nanobio interface. Colloids and Surfaces B: Biointerfaces, 123, 143–149. https://doi.org/10.1016/j.colsurfb.2014.09.046

Bove, P., Malvindi, M. A., Kote, S. S., & others. (2017). Dissolution test for risk assessment of nanoparticles: A pilot study. Nanoscale, 9(19), 6315–6326. https://doi.org/10.1039/C7NR01194C

Costa, P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123–133. https://doi.org/10.1016/S0928-0987(01)00095-1

Danhier, F., Ansorena, E., Silva, J. M., & others. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043

Dokmeci, M. R., & Khademhosseini, A. (2014). Organ-on-a-chip platforms for studying drug delivery systems. Journal of Controlled Release, 190, 210–225. https://doi.org/10.1016/j.jconrel.2014.05.004

Dressman, J. B., & Reppas, C. (2000). *In vitro–in vivo* correlations for lipophilic, poorly water-soluble drugs. European Journal of Pharmaceutical Sciences, 11(Suppl 2), S73–S80. https://doi.org/10.1016/S0928-0987(00)00187-4

Emami, J. (2006). *In vitro–in vivo* correlation: From theory to applications. Journal of Pharmacy & Pharmaceutical Sciences, 9(2), 169–189. https://doi.org/10.18433/J3PS3R

European Medicines Agency. (2013). Reflection paper on the data requirements for intravenous liposomal products (EMA/CHMP/806058/2009). https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-liposomal-products_en.pdf

European Medicines Agency. (2014). Guideline on quality of oral modified release products (EMA/CHMP/QWP/428693/2013). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf

U.S. Food and Drug Administration, Office of Generic Drugs. (2020). *In vitro* release test methods for liposomal drug products (Research Report). https://www.fda.gov/media/144820/download

U.S. Food and Drug Administration. (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. https://www.fda.gov/media/70936/download

U.S. Food and Drug Administration. (2014). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs — General considerations. https://www.fda.gov/media/88254/download

FDA. (1997). Guidance for industry: Extended-release oral dosage forms: Development, evaluation, and application of *in vitro/in vivo* correlations. U.S. Department of Health and Human Services.

Fecioru, E., Klein, M., Krämer, J., & Wacker, M. G. (2019). *In vitro* performance testing of nanoparticulate drug products for parenteral administration. Dissolution Technologies, 26(3), 28–37. https://doi.org/10.14227/DT260319P28

Gohel, M., Sarvaiya, K., & Shah, A. (2009). Development of modified dissolution apparatus for liposomal and nanoparticulate drug delivery systems. AAPS PharmSciTech, 10(2), 255–263. https://doi.org/10.1208/s12249-009-9218-z

Grassi, M., Magarotto, L., Farra, R., et al. (2021). A microfluidic system for dissolution testing of microparticles. European Journal of Pharmaceutical Sciences, 163, 105861. https://doi.org/10.1016/j.ejps.2021.105861

Gray, V., Cady, S., Curran, D., et al. (2018). *In vitro* release test methods for drug formulations for parenteral applications. Dissolution Technologies, 25(4), 8–13. https://doi.org/10.14227/DT250418P8

Gupta, R., Chen, Y., & Xie, H. (2021). *In vitro* dissolution considerations associated with nano drug delivery systems (NDDS). Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 13(6), e1732. https://doi.org/10.1002/wnan.1732

Haddouchi, S. (2015, August 31–September 1). Dissolution testing for novel drug delivery systems [Conference presentation]. Disso India 2015 Conference, Goa, India.

Hsu, L. R., Chow, D., Zahid, M., et al. (2024). *In vitro* release testing methods for colloidal drug carriers: Challenges and opportunities. Pharmaceutics, 16(1), 103. https://doi.org/10.3390/pharmaceutics16010103

Hsu, L. R., Chow, D., Zahid, M., et al. (2024). *In vitro* release testing methods for colloidal drug carriers: The lack of standardized protocols. Pharmaceutics, 16(1), 103. https://doi.org/10.3390/pharmaceutics16010103

Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315.

International Conference on Harmonisation (ICH). (2009). ICH harmonised tripartite guideline: Pharmaceutical development Q8(R2).

Kambhampati, S. P., & Kannan, R. (2013). Biorelevant dissolution media and *in vitro–in vivo* correlation in drug release. Current Drug Delivery, 10(1), 68–76. https://doi.org/10.2174/1567201811310010011

Macheras, P., & Iliadis, A. (2006). Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: Homogeneous and heterogeneous approaches. Springer.

Mandula, H., Ramana Reddy, B., & Venkateswarlu, B. (2020). Near-infrared spectroscopy for prediction of dissolution profiles. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 241, 118673. https://doi.org/10.1016/j.saa.2020.118673

Marques, M. R. C., Loebenberg, R., & Almukainzi, M. (2011). Simulated biological fluids with possible application in dissolution testing. Dissolution Technologies, 18(3), 15–28. https://doi.org/10.14227/DT180311P15

Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews, 54(Suppl 1), S131–S155. https://doi.org/10.1016/S0169-409X(02)00118-7

Nothnagel, L., & Wacker, M. G. (2018). How to measure release from nanosized carriers. Journal of Controlled Release, 286, 112–125. https://doi.org/10.1016/j.jconrel.2018.07.016

Petros, R. A., & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), 615–627. https://doi.org/10.1038/nrd2591

Rowland, M., & Tozer, T. N. (2010). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (4th ed.). Lippincott Williams & Wilkins.

Shargel, L., Wu-Pong, S., & Yu, A. B. C. (2015). Applied biopharmaceutics & pharmacokinetics (7th ed.). McGraw-Hill.

Shen, J., & Burgess, D. J. (2013). *In vitro* dissolution testing strategies for nanoparticulate drug delivery systems: Recent developments and challenges. Drug Delivery and Translational Research, 3(5), 409–415. https://doi.org/10.1007/s13346-013-0131-4

Tistaert, C., Roose, M., Vertommen, J., et al. (2021). Predicting pharmacokinetics of pediatric formulations via PBPK modeling. Journal of Pharmaceutical Sciences, 110(2), 742–753. https://doi.org/10.1016/j.xphs.2020.10.027

Tiwari, G., Tiwari, R., Srivastava, B., et al. (2010). Analytical techniques for in situ monitoring of dissolution. Journal of Pharmacy & Bioallied Sciences, 2(4), 238–246. https://doi.org/10.4103/0975-7406.72131

United States Pharmacopeia. (2020). <711> Dissolution. USP 43–NF 38. USP Convention.

Vyshnavi, K., Sinduja, Y., Adeyemi, P. G., et al. (2022). A review article on dissolution studies in novel drug delivery system. Journal of Drug Delivery and Therapeutics, 12(3), 220–225. https://doi.org/10.22270/jddt.v12i3.5339

Yu, L. X., Amidon, G. L., Polli, J. E., et al. (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharmaceutical Research, 19(7), 921–925. https://doi.org/10.1023/A:1016394826192